Publication detail

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement

MIZERA, J. GENZOR, S. SOVA, M. STANKE, L. BURGET, R. JAKUBEC, P. VYKOPAL, M. POBEHA, P. ZAPLETALOVÁ, J.

Original Title

The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement

Type

journal article in Web of Science

Language

English

Original Abstract

RationalePersistent respiratory symptoms following Coronavirus Disease 2019 (COVID-19) are associated with residual radiological changes in lung parenchyma, with a risk of development into lung fibrosis, and with impaired pulmonary function. Previous studies hinted at the possible efficacy of corticosteroids (CS) in facilitating the resolution of post-COVID residual changes in the lungs, but the available data is limited.AimTo evaluate the effects of CS treatment in post-COVID respiratory syndrome patients.Patients and methodsPost-COVID patients were recruited into a prospective single-center observational study and scheduled for an initial (V1) and follow-up visit (V2) at the Department of Respiratory Medicine and Tuberculosis, University Hospital Olomouc, comprising of pulmonary function testing, chest x-ray, and complex clinical examination. The decision to administer CS or maintain watchful waiting (WW) was in line with Czech national guidelines.ResultsThe study involved 2729 COVID-19 survivors (45.7% male; mean age: 54.6). From 2026 patients with complete V1 data, 131 patients were indicated for CS therapy. These patients showed significantly worse radiological and functional impairment at V1. Mean initial dose was 27.6 mg (SD +/- 10,64), and the mean duration of CS therapy was 13.3 weeks (SD +/- 10,06). Following therapy, significantly better improvement of static lung volumes and transfer factor for carbon monoxide (DLCO), and significantly better rates of good or complete radiological and subjective improvement were observed in the CS group compared to controls with available follow-up data (n = 894).ConclusionBetter improvement of pulmonary function, radiological findings and subjective symptoms were observed in patients CS compared to watchful waiting. Our findings suggest that glucocorticoid therapy could benefit selected patients with persistent dyspnea, significant radiological changes, and decreased DLCO.

Keywords

Post-covid syndrome; Pulmonary fbrosis; Corticosteroids; statistics

Authors

MIZERA, J.; GENZOR, S.; SOVA, M.; STANKE, L.; BURGET, R.; JAKUBEC, P.; VYKOPAL, M.; POBEHA, P.; ZAPLETALOVÁ, J.

Released

5. 2. 2024

Publisher

BioMed Central

ISBN

2200-6133

Periodical

Pneumonia

Year of study

16

Number

1

State

Australia

Pages from

1

Pages to

10

Pages count

10

URL

https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7

Full text in the Digital Library

http://hdl.handle.net/11012/245495

BibTex

@article{BUT187604,
  author="Jan {Mizera} and Samuel {Genzor} and Milan {Sova} and Ladislav {Stanke} and Radim {Burget} and Petr {Jakubec} and Martin {Vykopal} and Pavol {Pobeha} and Jana {Zapletalová}",
  title="The effectiveness of glucocorticoid treatment in post-COVID-19 pulmonary involvement",
  journal="Pneumonia",
  year="2024",
  volume="16",
  number="1",
  pages="1--10",
  doi="10.1186/s41479-023-00123-7",
  issn="2200-6133",
  url="https://pneumonia.biomedcentral.com/articles/10.1186/s41479-023-00123-7"
}